Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.

abstract：PURPOSE:Although eribulin is a suitable option for early-line treatment of metastatic breast cancer (MBC), data on first- or second-line use of eribulin for human epidermal growth factor receptor 2 (HER2)-negative MBC are still limited. Therefore, we conducted a phase II trial to investigate the efficacy and safety of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kimura K,Iwamoto M,Tanaka S,Yamamoto D,Yoshidome K,Ogura H,Terasawa R,Matsunami N,Takahashi Y,Nitta T,Morimoto T,Fujioka H,Kawaguchi K,Uchiyama K

更新日期：2018-05-01 00:00:00

abstract：:Carmustine (BCNU) has proved to be of value against a variety of primary brain tumors. This agent exhibits a steep dose-response curve in in vitro and animal tumor models and has been proposed for use in high-dose chemotherapy as a single agent or in combination. We conducted a phase II study to assess high-dose BCNU ...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffet E,Khelfaoui F,Philip I,Biron P,Brunat-Mentigny M,Philip T

更新日期：1997-01-01 00:00:00

abstract：:The subjects were 35 patients with unresectable hepatocellular carcinoma. The patients were divided into a transcatheter arterial embolization group (TAE group, 18 cases) and a combination therapy group receiving both TAE and percutaneous ethanol injection therapy (TAE+PEIT group, 17 cases). The 50% survival period wa...

journal_title：Cancer chemotherapy and pharmacology

authors： Tateishi H,Kinuta M,Furukawa J,Takata N,Maruyama H,Oi H,Yayoi E,Okamura J

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:As reported, epidermal growth factor receptor (EGFR) is over expressed in a variety of cancers including esophageal squamous cell carcinoma. Therefore, it becomes one of the potential targets for treating esophageal cancer. Pingyangmycin (PYM), a single A5 component of bleomycin, is currently used for the treat...

journal_title：Cancer chemotherapy and pharmacology

authors： Gong JH,Liu XJ,Li Y,Zhen YS

更新日期：2012-05-01 00:00:00

abstract：:Relationships between in vitro chemosensitivity and cell nuclear DNA content were investigated in malignant cells from 41 patients exhibiting advanced gastric carcinoma. The chemosensitivity was evaluated by measuring the succinate dehydrogenase (SD) activity in drug-exposed cancer cells and the DNA content was micros...

journal_title：Cancer chemotherapy and pharmacology

authors： Saito A,Korenaga D,Maehara Y,Baba H,Okamura T,Sugimachi K

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:The safety of S-1 in recurrent colorectal cancer patients with chronic myeloid leukemia (CML) treated with dasatinib has not been established. We evaluated the safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with CML treated with dasatinib. PATIENT:A 70-year-old man had undergone surgery...

journal_title：Cancer chemotherapy and pharmacology

authors： Sueda T,Kudo T,Sakai D,Uemura M,Nishimura J,Hata T,Takemasa I,Mizushima T,Yamamoto H,Ezoe S,Matsumoto K,Doki Y,Mori M,Satoh T

更新日期：2014-12-01 00:00:00

abstract：:Thymidine (dThd) concentrations have been measured in the sera of normal subjects and solid tumor cancer patients by means of a sensitive high-pressure liquid chromatographic assay to determine whether natural and methotrexate (MTX)-induced fluctuations were large enough to alter the toxicity of MTX to marrow. The mea...

journal_title：Cancer chemotherapy and pharmacology

authors： Howell SB,Mansfield SJ,Taetle R

更新日期：1981-01-01 00:00:00

abstract：OBJECTIVE:We evaluated the efficacy and safety of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced metastatic transitional cell carcinoma of the urothelium. SUBJECTS AND METHODS:The subjects were 12 patients diagnosed with advanced metastatic transitional cell carcinoma of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamada Y,Itoh Y,Aoki S,Nakamura K,Taki T,Naruse K,Tobiume M,Zennami K,Katsuda R,Kato Y,Watanabe M,Nishikawa G,Minami M,Nakahira M,Ukai S,Sawada M,Kitamura A,Honda N

更新日期：2009-11-01 00:00:00

abstract：PURPOSE:Capecitabine is a prodrug that undergoes metabolism in three steps to form an active 5-fluorouracil (5-FU). The first step is primarily catalyzed by liver carboxylesterases (CES) 1. Here, we examined the effects of CES1 variants on pharmacokinetics and toxicity of capecitabine. METHODS:We enrolled postoperativ...

journal_title：Cancer chemotherapy and pharmacology

authors： Matsumoto N,Kubota Y,Ishida H,Sekido M,Ohkuma R,Ishiguro T,Hirasawa Y,Ariizumi H,Tsunoda T,Ikusue T,Kobayashi K,Hisamatsu A,Toshima H,Shimada K,Fujita KI

更新日期：2020-06-01 00:00:00

abstract：PURPOSE:Thalidomide has recently shown significant promise in the treatment of some types of cancer, and trials in combination with conventional chemotherapy are being undertaken. We wished to determine whether thalidomide potentiated the effect of cyclophosphamide, a commonly used cytotoxic drug, in a murine tumour mo...

journal_title：Cancer chemotherapy and pharmacology

authors： Ding Q,Kestell P,Baguley BC,Palmer BD,Paxton JW,Muller G,Ching LM

更新日期：2002-09-01 00:00:00

abstract：PURPOSE:Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (>60 years) would be reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Beumer JH,Owzar K,Lewis LD,Jiang C,Holleran JL,Christner SM,Blum W,Devine S,Kolitz JE,Linker C,Vij R,Alyea EP,Larson RA,Ratain MJ,Egorin MJ

更新日期：2014-11-01 00:00:00

abstract：PURPOSE:It has recently been recognised that anticancer chemotherapy can elicit an immunogenic form of apoptosis characterised by the exposure of calreticulin (CRT) on the surface of dying tumour cells, entailing an immune response that contributes to the therapeutic outcome. CRT exposure has been found to be induced b...

journal_title：Cancer chemotherapy and pharmacology

authors： Sonnemann J,Gressmann S,Becker S,Wittig S,Schmudde M,Beck JF

更新日期：2010-08-01 00:00:00

abstract：:A total of 26 evaluable patients with previously untreated, non-resectable adenocarcinoma of the lung were given 80 mg/m2 i.v. teniposide daily for 5 days every 3 weeks. Three partial responses (11%) were obtained that lasted for 12, 11 and 32 weeks, respectively. Leucopenia was the dose-limiting side effect, with WBC...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen JB,Bach F,Dombernowsky P,Hansen HH

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:Evasion to new treatments of advanced melanoma is still associated with a poor prognosis. Choosing the best combination of agents that can bypass resistance mechanisms remains a challenge. Sphaeropsidin A (Sph A) is a fungal bioactive secondary metabolite previously shown to force melanoma cells to undergo apop...

journal_title：Cancer chemotherapy and pharmacology

authors： Ingels A,Dinhof C,Garg AD,Maddau L,Masi M,Evidente A,Berger W,Dejaegher B,Mathieu V

更新日期：2017-05-01 00:00:00

abstract：PURPOSE:Chemosensitizers such as cyclosporin A can increase intracellular accumulation of chemotherapeutic agents such as Adriamycin in certain multidrug-resistant (MDR) cell lines with overexpression of P-glycoprotein. It is likely that, when combined with cyclosporin A, hyperthermia could increase membrane permeabili...

journal_title：Cancer chemotherapy and pharmacology

authors： Larrivée B,Averill DA

更新日期：2000-01-01 00:00:00

abstract：:A three-compartment model was fitted to idarubicin data in a NONMEM pooled-data approach. Clearance (CL) of 221.7 ml/min was relatively high, and drug distribution was rapid (CLD = 248.3 ml/min) and extensive [steady-state volume of distribution (Vss) 24 1]. The area under the concentration-time curve (AUC) of idarbic...

journal_title：Cancer chemotherapy and pharmacology

authors： Looby M,Linke R,Weiss M

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:The purpose of this article is to report the first case of markedly increased anticoagulant activity of warfarin when used in combination with doxifluridine, given as a replacement for capecitabine. METHODS:International normalized ratio (INR) of a 73-year-old female patient receiving warfarin was increased af...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakajima M,Genda T,Suehira M,Satoh H,Miki A,Hori S,Sawada Y

更新日期：2010-10-01 00:00:00

abstract：:Previous studies of irinotecan pharmacogenetics have shown that the UGT1A1*28 polymorphism has an effect on irinotecan (IRI)-induced toxicities in Caucasians. Yet compared with the UGT1A1*6 mutation, the UGT1A1*28 occurs at a much lower frequency in the Asians. Whether UGT1A1*6 and UGT1A1*28 are associated with IRI-in...

journal_title：Cancer chemotherapy and pharmacology

authors： Chen X,Liu L,Guo Z,Liang W,He J,Huang L,Deng Q,Tang H,Pan H,Guo M,Liu Y,He Q,He J

更新日期：2017-06-01 00:00:00

abstract：:The pharmacokinetics of pentamethylmelamine (PMM) have been investigated in mouse (Balb C-, CBA/LAC, nude), rat (Wistar), and man. In all three species, PMM was extensively demethylated to N2,N2,N4,N6-tetramethylmelamine and N2,N4,N6-trimethylmelamine, although marked species differences in the rate of metabolism were...

journal_title：Cancer chemotherapy and pharmacology

authors： Rutty CJ,Newell DR,Muindi JR,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：:3-Deazaguanine (3-DG), a purine analogue, has unusual antitumor activity against experimental mammary tumor models and a number of other solid tumors. Others have shown that mutant CHO cells deficient in hypoxanthine guanine phosphoribosyl transferase (HGPRTase) or adenine phosphoribosyl transferase (APRTase) are resi...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh G,Luna MK,Ardalan B

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:Seviteronel is an orally-administered selective cytochrome P450c17a 17,20-lyase and androgen receptor inhibitor with anti-tumor activity in vitro and in vivo, and clinical activity in men with advanced castration-resistant prostate cancer (CRPC) and men and women with advanced breast cancer. The purpose of this...

journal_title：Cancer chemotherapy and pharmacology

authors： Peer CJ,Schmidt KT,Kindrick JD,Eisner JR,Brown VV,Baskin-Bey E,Madan R,Figg WD

更新日期：2019-10-01 00:00:00

abstract：PURPOSE:To evaluate the efficacy and safety of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin. METHODS:The FOLFIRI regimen consisted of intravenous infusion of irinotecan 180 mg/m(2) on day 1 plus leucovorin (LV) 400 mg/m(2) on day 1 plus 5-fluorouracil (5-FU...

journal_title：Cancer chemotherapy and pharmacology

authors： Bao HY,Fang WJ,Zhang XC,Shi GM,Huang S,Yu LF,Chen J,Mou HB,Deng J,Shen P,Xu N

更新日期：2011-01-01 00:00:00

abstract：:The nephrotoxic interaction between cis-diamminedichloroplatinum (CDDP) and amikacin (AMI) was studied in rats. Following a single dose of CDDP (5 mg/kg i.v.), AMI (60 mg/kg s.c.) was given for 14 days. When given alone CDDP caused a 40% fall in the glomerular filtration rate (GFR), whereas AMI alone had no effect on ...

journal_title：Cancer chemotherapy and pharmacology

authors： Jongejan HT,Provoost AP,Molenaar JC

更新日期：1988-01-01 00:00:00

abstract：:The technique of alkaline elution was employed to study the interactions of methylene dimethane sulphonate (MDMS) and formaldehyde (HCHO) with DNA from Yoshida lymphosarcoma cells treated with these agents. MDMS and HCHO produced a proteinase sensitive filter retention which indicated the presence of DNA-protein cross...

journal_title：Cancer chemotherapy and pharmacology

authors： O'Connor PM,Fox BW

更新日期：1987-01-01 00:00:00

abstract：PURPOSE:Fenretinide is a synthetic retinoid with activity in prostate cancer and other cell lines. The aim of this study was to assess the efficacy and tolerability of fenretinide in chemotherapy-naïve men with hormone refractory prostate cancer. METHODS:Eligibility criteria included hormone refractory prostate cancer...

journal_title：Cancer chemotherapy and pharmacology

authors： Moore MM,Stockler M,Lim R,Mok TS,Millward M,Boyer MJ

更新日期：2010-10-01 00:00:00

abstract：PURPOSE:Cisplatin and radiation therapy remain the current standard for treating locally advanced SCCHN. Novel treatment approaches are needed, especially in patients with human papilloma virus (HPV)-negative disease who have worse outcomes despite multimodality therapy. METHODS:Using our institutional review board ap...

journal_title：Cancer chemotherapy and pharmacology

authors： Patel K,Wen J,Magliocca K,Muller S,Liu Y,Chen ZG,Saba N,Diaz R

更新日期：2014-11-01 00:00:00

abstract：PURPOSE:To compare the response rates, toxicities and survival durations of elderly patients (70 years of age or more) with those of younger patients (less than 70 years of age) with non-small-cell lung cancer (NSCLC) treated with cisplatin-based chemotherapy. PATIENTS AND METHODS:We analyzed retrospectively the data ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kubota K,Furuse K,Kawahara M,Kodama N,Ogawara M,Takada M,Masuda N,Negoro S,Matsui K,Takifuji N,Kudoh S,Kusunoki Y,Fukuoka M

更新日期：1997-01-01 00:00:00

abstract：:The intestinal absorption of 6-mercaptopurine and its nucleoside 6-mercaptopurine riboside has been studied in the rat with the in situ dual luminal and vascular perfusion. 6-Mercaptopurine is an inactive prodrug that requires intestinal absorption, cellular uptake and intracellular anabolism for cytotoxic activity. V...

journal_title：Cancer chemotherapy and pharmacology

authors： Pennington AM,Bronk JR

更新日期：1995-01-01 00:00:00

abstract：PURPOSE:Icotinib is a new first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. A phase II study was conducted to evaluate the efficacy and safety of icotinib in combination with whole-brain radiotherapy (WBRT) in Chinese NSCLC patients with brain metastases (BMs); the cerebrospinal fluid...

journal_title：Cancer chemotherapy and pharmacology

authors： Fan Y,Huang Z,Fang L,Miao L,Gong L,Yu H,Yang H,Lei T,Mao W

更新日期：2015-09-01 00:00:00

abstract：:The present paper reviews several studies performed between 1977 and 1986 in Singapore on the 10-year survival outcome of treatment for stage I and II hepatocellular carcinoma (HCC). Of 801 HCC patients evaluated, only 2 survivors (0.3%) remained in complete remission for 13 and 14 years, respectively. One had receive...

journal_title：Cancer chemotherapy and pharmacology

authors： Oon CJ

更新日期：1992-01-01 00:00:00